Recordati gets FDA approval; Kindler named PhRMA chairman;

  @FierceBiotech: Roche/Genentech try to develop companion diagnostic tests for all their experimental drugs. | Follow @FierceBiotech

 @JohnCFierce: I'm keeping my fingers crossed that this time the FDA is going to follow through on supporting innovation. It's been a long time coming. Report | Follow @JohnCFierce

> The FDA has approved Recordati's Carbaglu (carglumic acid) in pediatric and adult patients for the treatment of acute hyperammonaemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS deficiency) and as maintenance therapy for chronic hyperammonaemia due to NAGS deficiency. Recordati release

> Ohio will lose 250 jobs as Warner Chilcott moves the recently purchased Proctor & Gamble drug unit to the company's headquarters in Rockaway, NJ. Report

> Takeda has withdrawn its European marketing applications for Type 2 diabetes drug Competact. Report

> Pfizer chief Jeffrey Kindler has been elected chairman of PhRMA, succeeding David Brennan, AstraZeneca's CEO. Release

> European drugs regulators have recommended that the cancer drug Tarceva from OSI Pharmaceuticals and Roche be marketed for first-line maintenance of patients with locally advanced or metastatic non-small-cell lung cancer. Release

> Valeant Pharmaceuticals says it will buy a Brazilian generic and OTC drugmaker for about $28 million to expand its generics and dermatology portfolio. Release

And Finally... Loneliness is linked to higher blood pressure, according to a new study. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.